keyword
https://read.qxmd.com/read/35745827/two-layer-sustained-release-microneedles-encapsulating-exenatide-for-type-2-diabetes-treatment
#21
JOURNAL ARTICLE
Han Liu, Suohui Zhang, Zequan Zhou, Mengzhen Xing, Yunhua Gao
Daily administration of multiple injections can cause inconvenience and reduce compliance in diabetic patients; thus, microneedle (MN) administration is favored due to its various advantages. Accordingly, the two-layer sustained-release MNs (TS-MNs) were fabricated by encapsulating exenatide (EXT) in calcium alginate (CA) gel in this work. The TS-MNs were composed of a sodium alginate (SA) tip and a water-soluble matrix-containing calcium chloride (CaCl2 ). Subsequently, the calcium ion (Ca2+ ) contained in the matrix layer penetrated the tip layer for cross-linking, leaving the drug in the cross-linked network...
June 13, 2022: Pharmaceutics
https://read.qxmd.com/read/35512849/the-antiobesity-effect-and-safety-of-glp-1-receptor-agonist-in-overweight-obese-patients-without-diabetes-a-systematic-review-and-meta-analysis
#22
JOURNAL ARTICLE
Xiaonan Guo, Zhibo Zhou, Xiaorui Lyu, Hanyuan Xu, Huijuan Zhu, Hui Pan, Linjie Wang, Hongbo Yang, Fengying Gong
Aim To determine the antiobesity effect and safety of glucagon-like peptide-1 receptor agonist (GLP-1RA) including liraglutide, exenatide and semaglutide treatment in overweight/obese patients without diabetes. The random-effect model was used to pool data extracted from included literatures. The weighted mean difference (WMD), odds ratio and 95% confidence interval (CI) were used to present the meta-analysis results (PROSPERO registration number: CRD 42020173199). The sources of intertrial heterogeneity, bias and the robustness of results were evaluated by subgroup analysis, sensitivity analysis and regression analysis, respectively...
July 2022: Hormone and Metabolic Research
https://read.qxmd.com/read/34741929/polyvascular-disease-and-increased-risk-of-cardiovascular-events-in-patients-with-type-2-diabetes-insights-from-the-exscel-trial
#23
JOURNAL ARTICLE
Marc D Samsky, Robert J Mentz, Amanda Stebbins, Yuliya Lokhnygina, Aaron W Aday, Neha J Pagidipati, W Schuyler Jones, Brian G Katona, Manesh R Patel, Rury R Holman, Adrian F Hernandez, Jorge Antonio Gutierrez
BACKGROUND AND AIMS: Polyvascular disease is an independent predictor of major adverse cardiovascular events (MACE). The relationship between the number of diseased arterial beds and MACE is unknown. How MACE risk changes in individuals with type 2 diabetes (T2D) is also understudied. Furthermore, it is unknown whether heart failure (HF) status and hemoglobin A1c (HbA1c) levels influence outcomes in polyvascular disease. This analysis from the Exenatide Study of Cardiovascular Event Lowering trial (EXSCEL) aimed to examine the risk associated with increasing number of diseased arterial beds on MACE and all-cause mortality (ACM)...
December 2021: Atherosclerosis
https://read.qxmd.com/read/34526024/glp-1-receptor-agonists-and-cardiorenal-outcomes-in-type-2-diabetes-an-updated-meta-analysis-of-eight-cvots
#24
JOURNAL ARTICLE
Dario Giugliano, Lorenzo Scappaticcio, Miriam Longo, Paola Caruso, Maria Ida Maiorino, Giuseppe Bellastella, Antonio Ceriello, Paolo Chiodini, Katherine Esposito
BACKGROUND: A meta-analysis is presented of cardiovascular outcome trials (CVOTs) comparing glucagon-like peptide-1 receptor agonists (GLP-1RA) versus placebo on cardiorenal outcomes in patients with type 2 diabetes mellitus (T2DM). METHODS: We did an electronic search up to June 30, 2021, for eligible trials. We did a meta-analysis of available trial data using a random-effects model to calculate overall hazard ratios (HRs) and 95% CI (confidence intervals). We included data from 8 CVOTs and 60,080 patients (72...
September 15, 2021: Cardiovascular Diabetology
https://read.qxmd.com/read/34144086/glp-1-receptor-agonists-for-cardiovascular-outcomes-with-and-without-metformin-a-systematic-review-and-meta-analysis-of-cardiovascular-outcomes-trials
#25
JOURNAL ARTICLE
Apostolos Tsapas, Thomas Karagiannis, Ioannis Avgerinos, Aris Liakos, Eleni Bekiari
AIMS: To explore the effect of background treatment with metformin on the efficacy of GLP-1 receptor agonists (GLP-1 RAs) on cardiovascular outcomes in type 2 diabetes. METHODS: We searched MEDLINE and EMBASE through May 5, 2021 for randomized, placebo-controlled, cardiovascular outcomes trials of GLP-1 RAs in patients with type 2 diabetes that reported cardiovascular or mortality outcomes by baseline metformin use. Main outcome was incidence of major adverse cardiovascular events (MACE)...
July 2021: Diabetes Research and Clinical Practice
https://read.qxmd.com/read/34142743/feasibility-of-once-weekly-exenatide-lar-and-enhanced-diabetes-care-in-indigenous-australians-with-type-2-diabetes-long-acting-once-weekly-exenatide-lar-sugar-lower-sugar-study
#26
JOURNAL ARTICLE
Elif I Ekinci, Felicity Pyrlis, Mariam Hachem, Louise J Maple-Brown, Alex Brown, Graeme Maguire, Leonid Churilov, Neale Cohen
BACKGROUND: Diabetes is 3-4 times more prevalent in Indigenous Australians with blood glucose levels often above target range. Once weekly formulations of exenatide(exenatide-LAR) have demonstrated significantly greater improvements in glycaemic management with no increased risk of hypoglycaemia and with reductions in bodyweight but have not been studied in Indigenous Australians. AIMS: To assess the feasibility and metabolic effects of once weekly supervised injection of exenatide-LAR in addition to standard care in Indigenous Australians with type 2 diabetes...
September 2021: Internal Medicine Journal
https://read.qxmd.com/read/34106786/impaired-ca-2-signaling-due-to-hepatic-steatosis-mediates-hepatic-insulin-resistance-in-alstr%C3%A3-m-syndrome-mice-that-is-reversed-by-glp-1-analog-treatment
#27
JOURNAL ARTICLE
Eunus S Ali, Dorothée Girard, Nikolai Petrovsky
Ca2+ signaling plays a critical role in the regulation of hepatic metabolism by hormones including insulin. Changes in cytoplasmic Ca2+ regulate synthesis and posttranslational modification of key signaling proteins in the insulin pathways. Emerging evidence suggests that hepatocyte intracellular Ca2+ signaling is altered in lipid-loaded liver cells isolated from obese rodent models. The mechanisms of altered Ca2+ -insulin and insulin-Ca2+ signaling pathways in obesity remain poorly understood. Here, we show that the kinetics of insulin-initiated intracellular (initial) Ca2+ release from endoplasmic reticulum is significantly impaired in steatotic hepatocytes from obese Alström syndrome mice...
July 1, 2021: American Journal of Physiology. Cell Physiology
https://read.qxmd.com/read/34087552/facilitated-structure-verification-of-the-biopharmaceutical-peptide-exenatide-by-2d-heteronuclear-nmr-maps
#28
JOURNAL ARTICLE
Subrata H Mishra, Sitaram Bhavaraju, Dale R Schmidt, Kevin L Carrick
Exenatide is a peptide based anti-diabetic prescription medication. Until now, the literature has lacked a comprehensive atom-specific molecular characterization for this complex large peptide by NMR spectroscopy that can be effortlessly and rapidly utilized for biopharmaceutical structural veracity. Peptide structure verification by NMR is challenging and cumbersome when reliant on traditional proton-based methodology (through-bond and through-space proton connectivity) alone due to increasing complexity, low signal dispersion, and overlap...
September 5, 2021: Journal of Pharmaceutical and Biomedical Analysis
https://read.qxmd.com/read/34046446/safety-tolerability-and-proof-of-concept-study-of-okv-119-a-novel-exenatide-long-term-drug-delivery-system-in-healthy-cats
#29
JOURNAL ARTICLE
Michael Klotsman, Christopher A Adin, Wayne H Anderson, Chen Gilor
Background: Glucagon-like peptide-1 (GLP-1) is an incretin hormone that plays an important role in glucose homeostasis and food intake. In people, GLP-1 receptor agonists (GLP-1RAs) are commonly used for the treatment of type 2 diabetes mellitus (DM) and obesity; however, non-adherence to injectable medications is common. OKV-119 is an investigational drug delivery system intended for subdermal implantation and delivery of the GLP-1RA exenatide for up to 6 months. Hypothesis/Objectives: Develop protocols for the subcutaneous (SC) insertion and removal of OKV-119 and to evaluate its tolerability, in vivo drug-releasing characteristics, and weight-loss effects in cats...
2021: Frontiers in Veterinary Science
https://read.qxmd.com/read/34016830/effect-of-exenatide-use-on-cognitive-and-affective-functioning-in-obese-patients-with-type-2-diabetes-mellitus-exenatide-use-mediates-depressive-scores-through-increased-perceived-stress-levels
#30
JOURNAL ARTICLE
Candan Yasemin Eren-Yazicioglu, Buket Kara, Seda Sancak, Sanem Pinar Uysal, Dilek Yazici, Nalan Okuroglu, Alexis E Whitton, Ashleigh V Rutherford, Hale Yapici-Eser
PURPOSE/BACKGROUND: Glucagon-like peptide-1 (GLP-1) is a molecule used to treat type 2 diabetes mellitus (T2DM). Given their widespread expression in the nervous system, GLP-1 receptors also play a role in regulating mood and cognitive function. Here, we aimed to compare obese patients with T2DM, with or without exenatide (a GLP-1R agonist) use on cognitive and affective functioning. METHODS/PROCEDURES: A total of 43 patients with T2DM (23 on exenatide and 20 without exenatide) were evaluated with the Snaith-Hamilton Pleasure Scale, Cognitive Failures Questionnaire, Patient Health Questionnaire-9 (PHQ-9), Generalized Anxiety Disorder-7, Childhood Trauma Questionnaire, Perceived Stress Scale (PSS), and Chronic Stress Scale, in addition to laboratory-based measures of reward learning (the probabilistic reward task) and working memory (Letter-N-Back task)...
July 2021: Journal of Clinical Psychopharmacology
https://read.qxmd.com/read/34004254/comparative-effects-of-incretin-based-therapy-on-early-onset-diabetic-nephropathy-in-rats-role-of-tnf-%C3%AE-tgf-%C3%AE-and-c-caspase-3
#31
COMPARATIVE STUDY
Heba A Habib, Gehan H Heeba, Mohamed M A Khalifa
AIMS: Diabetic nephropathy, a major threat to diabetic patients, is considered as the main reason for end-stage renal disease. Fortunately, incretin-based therapy has been aroused as considerable source to attenuate diabetic renal damage. This study aimed to investigate whether superior protective effects on the progression of diabetic kidney are exerted by glucagon-like peptide-1 analog, exenatide, or dipeptidyl peptidase-4 inhibitor, sitagliptin. MATERIALS AND METHODS: Male Wistar rats were fed high-fat diet for 2 weeks followed by injection of low dose streptozotocin to induce type 2 diabetes mellitus...
August 1, 2021: Life Sciences
https://read.qxmd.com/read/34002953/insulin-resistance-limits-corneal-nerve-regeneration-in-patients-with-type-2-diabetes-undergoing-intensive-glycemic-control
#32
RANDOMIZED CONTROLLED TRIAL
Georgios Ponirakis, Muhammad A Abdul-Ghani, Amin Jayyousi, Mahmoud A Zirie, Salma Al-Mohannadi, Hamad Almuhannadi, Ioannis N Petropoulos, Adnan Khan, Hoda Gad, Osama Migahid, Ayman Megahed, Murtaza Qazi, Fatema AlMarri, Fatima Al-Khayat, Ziyad Mahfoud, Ralph DeFronzo, Rayaz A Malik
AIMS/INTRODUCTION: This study aimed to investigate whether insulin resistance (IR) in individuals with type 2 diabetes undergoing intensive glycemic control determines the extent of improvement in neuropathy. MATERIALS AND METHODS: This was an exploratory substudy of an open-label, randomized controlled trial of individuals with poorly controlled type 2 diabetes treated with exenatide and pioglitazone or insulin to achieve a glycated hemoglobin <7.0% (<53 mmol/mol)...
November 2021: Journal of Diabetes Investigation
https://read.qxmd.com/read/33926305/evaluation-of-glp-1-receptor-agonists-in-combination-with-multiple-daily-insulin-injections-for-type-2-diabetes
#33
JOURNAL ARTICLE
Kimberly Sassenrath, Beth Bryles Phillips, Rebecca H Stone
OBJECTIVE: To assess the available literature evaluating the efficacy and safety of glucagon-like peptide-1 receptor agonists (GLP-1 RAs) with multiple daily insulin injections (MDII). DATA SOURCES: A literature search of MEDLINE and Embase was performed (2004 to May 2020) using the following search terms: glucagon-like 1 receptor agonist, liraglutide, albiglutide, dulaglutide, exenatide, semaglutide, diabetes mellitus, and prandial insulin or bolus insulin. Additional references were obtained from cross-referencing the bibliographies of selected articles...
April 29, 2021: Journal of Pharmacy Practice
https://read.qxmd.com/read/33866119/cardioprotective-properties-of-glucagon-like-peptide-1-receptor-agonists-in-type-2-diabetes-mellitus-patients-a-systematic-review
#34
JOURNAL ARTICLE
Wynne Widiarti, Alverina Cynthia Sukmajaya, David Nugraha, Firas Farisi Alkaff
BACKGROUND AND AIMS: Cardiovascular disease is one of the main contributors for the mortality in type 2 diabetes mellitus (T2DM) patients. Glucagon-like peptide-1 receptor agonists (GLP-1 RAs) had shown cardiovascular benefits which may be advantageous to reduce mortality in T2DM patients. This systematic review focused on analyzing the effects of GLP-1 RAs on cardiovascular outcomes. METHODS: We conducted an extensive search through JSTOR, PubMed, Scopus, EBSCohost, and CENTRAL...
May 2021: Diabetes & Metabolic Syndrome
https://read.qxmd.com/read/33852204/insulin-secretion-is-a-strong-predictor-for-need-of-insulin-therapy-in-patients-with-new-onset-diabetes-and-hba1c-of-more-than-10-a-post-hoc-analysis-of-the-edict-study
#35
JOURNAL ARTICLE
Siham Abdelgani, Curtiss Puckett, John Adams, Curtis Triplitt, Ralph A DeFronzo, Muhammad Abdul-Ghani
AIM: To identify predictors of response to glucose-lowering therapy in patients with new-onset diabetes and very high HbA1c (>10%). METHODS: The study included EDICT participants with an initial HbA1c of more than 10% (N = 104). All subjects received a 75-g oral glucose tolerance test (OGTT) before initiation of therapy, and then were randomized to receive: (a) initial triple therapy with metformin, pioglitazone and exenatide versus (b) stepwise conventional therapy with metformin followed by glipizide and then glargine insulin to reduce HbA1c to less than 6...
July 2021: Diabetes, Obesity & Metabolism
https://read.qxmd.com/read/33841337/efficacy-of-various-hypoglycemic-agents-in-the-treatment-of-patients-with-nonalcoholic-liver-disease-with-or-without-diabetes%C3%AF-a-network-meta-analysis
#36
Jingxuan Lian, Jianfang Fu
Objective: To comprehensively evaluate and compare the therapeutic effects of various hypoglycemic agents in NAFLD patients with or without diabetes. Methods: All literature from the Cochrane Central Register of Controlled Trials (CENTRAL), PubMed, and Clinical Trials was searched, and the language was limited to English. Two reviewers independently assessed study eligibility, continuous data extraction, and independent assessment of bias risk. Our primary outcomes were alanine aminotransferase (ALT), aspartate aminotransferase (AST) and triglyceride levels, while our secondary outcomes were high-density lipoprotein (HDL) and low-density lipoprotein (LDL) levels, body weight, BMI, and fasting glucose and glycosylated hemoglobin (HbA1c) levels...
2021: Frontiers in Endocrinology
https://read.qxmd.com/read/33714226/painful-diabetic-neuropathy-is-associated-with-increased-nerve-regeneration-in-patients-with-type-2-diabetes-undergoing-intensive-glycemic-control
#37
RANDOMIZED CONTROLLED TRIAL
Georgios Ponirakis, Muhammad A Abdul-Ghani, Amin Jayyousi, Mahmoud A Zirie, Murtaza Qazi, Hamad Almuhannadi, Ioannis N Petropoulos, Adnan Khan, Hoda Gad, Osama Migahid, Ayman Megahed, Salma Al-Mohannadi, Fatema AlMarri, Fatima Al-Khayat, Ziyad Mahfoud, Hanadi Al Hamad, Marwan Ramadan, Ralph DeFronzo, Rayaz A Malik
AIMS/INTRODUCTION: Painful diabetic peripheral neuropathy (pDPN) is associated with small nerve fiber degeneration and regeneration. This study investigated whether the presence of pDPN might influence nerve regeneration in patients with type 2 diabetes undergoing intensive glycemic control. MATERIALS AND METHODS: This exploratory substudy of an open-label randomized controlled trial undertook the Douleur Neuropathique en 4 questionnaire and assessment of electrochemical skin conductance, vibration perception threshold and corneal nerve morphology using corneal confocal microscopy in participants with and without pDPN treated with exenatide and pioglitazone or basal-bolus insulin at baseline and 1-year follow up, and 18 controls at baseline only...
September 2021: Journal of Diabetes Investigation
https://read.qxmd.com/read/33690915/predicting-major-adverse-limb-events-in-individuals-with-type-2-diabetes-insights-from-the-exscel-trial
#38
JOURNAL ARTICLE
E Hope Weissler, Robert M Clare, Yuliya Lokhnygina, John B Buse, Shaun G Goodman, Brian Katona, Nayyar Iqbal, Neha J Pagidipati, Naveed Sattar, Rury R Holman, Adrian F Hernandez, Robert J Mentz, Manesh R Patel, W Schuyler Jones
AIMS: Although models exist to predict amputation among people with type 2 diabetes with foot ulceration or infection, we aimed to develop a prediction model for a broader range of major adverse limb events (MALE)-including gangrene, revascularization and amputation-among individuals with type 2 diabetes. METHODS: In a post-hoc analysis of data from the Exenatide Study of Cardiovascular Event Lowering (EXSCEL) trial, we compared participants who experienced MALE with those who did not...
October 2021: Diabetic Medicine: a Journal of the British Diabetic Association
https://read.qxmd.com/read/33513761/glucagon-like-peptide-1-receptor-agonists-for-treatment-of-nonalcoholic-fatty-liver-disease-and-nonalcoholic-steatohepatitis-an-updated-meta-analysis-of-randomized-controlled-trials
#39
REVIEW
Alessandro Mantovani, Graziana Petracca, Giorgia Beatrice, Alessandro Csermely, Amedeo Lonardo, Giovanni Targher
To assess the efficacy of glucagon-like peptide-1 receptor agonists (GLP-1 RAs) for treatment of nonalcoholic fatty liver disease (NAFLD) or steatohepatitis (NASH), we performed a systematic review and meta-analysis of randomized controlled trials (RCTs). Three large electronic databases were systematically searched (up to 15 December 2020) to identify placebo-controlled or active-controlled RCTs using different GLP-1 RAs. We included eleven placebo-controlled or active-controlled phase-2 RCTs (involving a total of 936 middle-aged individuals) that used liraglutide ( n = 6 RCTs), exenatide ( n = 3 RCTs), dulaglutide ( n = 1 RCT) or semaglutide ( n = 1 RCT) to specifically treat NAFLD or NASH, detected by liver biopsy ( n = 2 RCTs) or imaging techniques ( n = 9 RCTs)...
January 27, 2021: Metabolites
https://read.qxmd.com/read/33400403/neutral-effect-of-exenatide-on-serum-testosterone-in-men-with-type-2-diabetes-mellitus-a-prospective-cohort
#40
JOURNAL ARTICLE
Sky Graybill, Jennifer Hatfield, Maria Kravchenko, Darrick Beckman, Joshua Tate, Alexis Beauvais, Philip Clerc, Desarae Davila, Whitney Forbes, Jana Wardian, Matthew Kemm, Abegail Hubberd, Mark True
BACKGROUND: Endogenous testosterone increases with weight loss from diet, exercise, and bariatric surgery. However, little is known about testosterone levels after weight loss from medication. OBJECTIVES: Uncover the effects of Glucagon-Like Peptide-1 receptor agonist (GLP-1 RA) therapy on serum testosterone. MATERIALS AND METHODS: Prospective cohort study of men starting GLP-1 RA therapy for type 2 diabetes mellitus. RESULTS: 51 men lost 2...
January 5, 2021: Andrology
keyword
keyword
110086
2
3
Fetch more papers »
Fetching more papers... Fetching...
Remove bar
Read by QxMD icon Read
×

Save your favorite articles in one place with a free QxMD account.

×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"

We want to hear from doctors like you!

Take a second to answer a survey question.